AmoyDx® Pan Lung Cancer PCR Panel submission forregulatory approval in Japan for the additional indication ofAmivantamab in combination with chemotherapy

TOKYO and XIAMEN, October 8, 2025 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that they have submitted a partial change application to the MHLW (Ministry of Health, Labour and Welfare) for the AmoyDx^® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) for the additional indication of Amivantamab in combination with chemotherapy in Japan. Read the full story here:

JointRelease_EGFRins_Ami_application_E_fin.pdf

Download PDF • 207KB